173 related articles for article (PubMed ID: 3022916)
21. Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture.
Osborne CK; Boldt DH; Estrada P
Cancer Res; 1984 Apr; 44(4):1433-9. PubMed ID: 6704960
[TBL] [Abstract][Full Text] [Related]
22. Triphenylethylene antiestrogen binding sites (TABS) specificity.
Clark JH; Mitchell WC; Guthrie SC
J Steroid Biochem; 1987 Apr; 26(4):433-7. PubMed ID: 3586657
[TBL] [Abstract][Full Text] [Related]
23. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
Murphy CS; Parker CJ; McCague R; Jordan VC
Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
[TBL] [Abstract][Full Text] [Related]
24. Guide-lines in the design of new antiestrogens and cytotoxic-linked estrogens for the treatment of breast cancer.
Leclercq G; Devleeschouwer N; Heuson JC
J Steroid Biochem; 1983 Jul; 19(1A):75-85. PubMed ID: 6887875
[TBL] [Abstract][Full Text] [Related]
25. Growth inhibition and the regulation of cyclic AMP by the triphenylethylene anti-estrogen tamoxifen in the quail oviduct.
Fanidi A; Pageaux JF; Courion C; Fayard JM; Laugier C
Biol Cell; 1991; 72(1-2):181-6. PubMed ID: 1661631
[TBL] [Abstract][Full Text] [Related]
26. Sex steroid binding protein exerts a negative control on estradiol action in MCF-7 cells (human breast cancer) through cyclic adenosine 3',5'-monophosphate and protein kinase A.
Fortunati N; Fissore F; Fazzari A; Becchis M; Comba A; Catalano MG; Berta L; Frairia R
Endocrinology; 1996 Feb; 137(2):686-92. PubMed ID: 8593818
[TBL] [Abstract][Full Text] [Related]
27. Tamoxifen-resistant human breast cancer cell growth: inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13.
Strobl JS; Peterson VA
J Pharmacol Exp Ther; 1992 Oct; 263(1):186-93. PubMed ID: 1403784
[TBL] [Abstract][Full Text] [Related]
28. Alternative mechanisms of action of anti-oestrogens.
Colletta AA; Benson JR; Baum M
Breast Cancer Res Treat; 1994; 31(1):5-9. PubMed ID: 7981456
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase.
Lam HY
Biochem Biophys Res Commun; 1984 Jan; 118(1):27-32. PubMed ID: 6320825
[TBL] [Abstract][Full Text] [Related]
30. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
31. Antiestrogens prevent the stimulatory effects of L-triiodothyronine on cell proliferation.
Zhou-Li F; Albaladejo V; Joly-Pharaboz MO; Nicolas B; Andre J
Endocrinology; 1992 Mar; 130(3):1145-52. PubMed ID: 1537281
[TBL] [Abstract][Full Text] [Related]
32. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
Frankel LB; Lykkesfeldt AE; Hansen JB; Stenvang J
Breast Cancer Res Treat; 2007 Aug; 104(2):165-79. PubMed ID: 17061041
[TBL] [Abstract][Full Text] [Related]
33. Triphenylethylenes: a new class of protein kinase C inhibitors.
O'Brian CA; Liskamp RM; Solomon DH; Weinstein IB
J Natl Cancer Inst; 1986 Jun; 76(6):1243-6. PubMed ID: 3458960
[TBL] [Abstract][Full Text] [Related]
34. Effects of biologically active metabolites of tamoxifen on the proliferation kinetics of MCF-7 human breast cancer cells in vitro.
Reddel RR; Murphy LC; Sutherland RL
Cancer Res; 1983 Oct; 43(10):4618-24. PubMed ID: 6883318
[TBL] [Abstract][Full Text] [Related]
35. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
[TBL] [Abstract][Full Text] [Related]
36. Triphenylethylene antiestrogens induce uterine vascular endothelial growth factor expression via their partial estrogen agonist activity.
Hyder SM; Chiappetta C; Stancel GM
Cancer Lett; 1997 Dec; 120(2):165-71. PubMed ID: 9461033
[TBL] [Abstract][Full Text] [Related]
37. Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: involvement of the estrogen receptor.
Astruc ME; Chabret C; Bali P; Gagne D; Pons M
Endocrinology; 1995 Mar; 136(3):824-32. PubMed ID: 7867590
[TBL] [Abstract][Full Text] [Related]
38. Comparative analyses of mechanistic differences among antiestrogens.
Wijayaratne AL; Nagel SC; Paige LA; Christensen DJ; Norris JD; Fowlkes DM; McDonnell DP
Endocrinology; 1999 Dec; 140(12):5828-40. PubMed ID: 10579349
[TBL] [Abstract][Full Text] [Related]
39. Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors.
Frankfurt OS; Sugarbaker EV; Robb JA; Villa L
Cancer Lett; 1995 Nov; 97(2):149-54. PubMed ID: 7497456
[TBL] [Abstract][Full Text] [Related]
40. ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness.
Thompson EW; Katz D; Shima TB; Wakeling AE; Lippman ME; Dickson RB
Cancer Res; 1989 Dec; 49(24 Pt 1):6929-34. PubMed ID: 2582435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
